The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?

Basit Öğe Kaydı
dc.contributor.authorSen, Sedat
dc.contributor.authorTuncer, Asli
dc.contributor.authorOzakbas, Serkan
dc.contributor.authorUzunkopru, Cihat
dc.contributor.authorBaba, Cavid
dc.contributor.authorDemir, Serkan
dc.contributor.authorBeckmann, Yesim
dc.date.accessioned2024-04-24T16:15:39Z
dc.date.available2024-04-24T16:15:39Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known. Objective/methods: The aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed. Results: The study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found. Conclusion: In NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection.en_US
dc.identifier.doi10.1016/j.msard.2021.103399
dc.identifier.issn2211-0348
dc.identifier.issn2211-0356
dc.identifier.pmid35216782
dc.identifier.scopus2-s2.0-85122957692
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.msard.2021.103399
dc.identifier.urihttps://hdl.handle.net/11468/15884
dc.identifier.volume58en_US
dc.identifier.wosWOS:000793561600010
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofMultiple Sclerosis and Related Disorders
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNeuromyelitis Optica Spectrum Disordersen_US
dc.subjectMyelin Oligodendrocyte Glycoprotein Antibody-Associated Disordersen_US
dc.subjectDisease Modifying Treatmenten_US
dc.subjectCoronavirusen_US
dc.subjectSars-Cov-2en_US
dc.titleThe Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?en_US
dc.titleThe Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu